Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors
Open Access
- 5 April 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 9 (7) , 726-734
Abstract
Immune checkpoint inhibitors (ICI), which target immune regulatory pathways to unleash antitumor responses, have revolutionized cancer immunotherapy. Despite the remarkable success of ICI immunotherapy, a significant proportion of patients whose tumors respond to these treatments develop immune-related adverse events (irAE) resembling autoimmune diseases. Although the clinical spectrum of irAEs is well characterized, their successful management remains empiric. This is in part because the pathogenic mechanisms involved in the breakdown of peripheral tolerance and induction of irAEs remain elusive. Herein, we focused on regulatory T cells (Treg) in individuals with irAEs because these cells are vital for maintenance of peripheral tolerance, appear expanded in the peripheral blood of individuals with cancer, and abundantly express checkpoint molecules, hence representing direct targets of ICI immunotherapy. Our data demonstrate an intense transcriptomic reprogramming of CD4+CD25+CD127− Tregs in the blood of individuals with advanced metastatic melanoma who develop irAEs following ICI immunotherapy, with a characteristic inflammatory, apoptotic, and metabolic signature. This inflammatory signature was shared by Tregs from individuals with different types of cancer developing irAEs and individuals with autoimmune diseases. Our findings suggest that inflammatory Treg reprogramming is a feature of immunotherapy-induced irAEs, and this may facilitate translational approaches aiming to induce robust antitumor immunity without disturbing peripheral tolerance.Keywords
All Related Versions
Funding Information
- European Union's Horizon 2020 Research and Innovation program (947975)
- Post-Doctoral Researchers (166)
- European Union's Horizon 2020 Research and Innovation program (742390)
- European Union's Horizon 2020 Research and Innovation program (733100)
This publication has 19 references indexed in Scilit:
- Is autoimmunity the Achilles' heel of cancer immunotherapy?Nature Medicine, 2017
- Myeloid-derived suppressor cells and T regulatory cells in tumors: unraveling the dark side of the forceJournal of Leukocyte Biology, 2017
- Regulatory T cells in cancer immunotherapyCell Research, 2016
- Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory CellsImmunity, 2016
- Immunometabolism of regulatory T cellsNature Immunology, 2016
- Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthoodProceedings of the National Academy of Sciences, 2016
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with OutcomesClinical Cancer Research, 2016
- Immune-related adverse events with immune checkpoint blockade: a comprehensive reviewEuropean Journal of Cancer, 2016
- Distinct metabolic programs in activated T cells: opportunities for selective immunomodulationImmunological Reviews, 2012
- The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3Nature Genetics, 2001